ClinicalTrials.gg
RecruitingNCT07771140Updated Aug 18, 2026

A Phase I Clinical Trial to Evaluate HECN30227 Injection in Healthy Subjects and Subjects With Chronic Hepatitis B

A Phase 1 interventional study of HECN30227 injection(SAD) and Placebo(MAD) in HBV Infection, sponsored by Sunshine Lake Pharma Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Sunshine Lake Pharma Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Dec 2025, registered Aug 2026).
  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To evaluate the safety, efficacy, pharmacokinetics and immunogenicity of single and multiple doses of HECN30227 Injection in healthy volunteers and patients with chronic hepatitis B

02

Conditions studied

  • HBV Infection
03

In context

Lead sponsor

Sunshine Lake Pharma Co., Ltd. is the lead sponsor of 83 studies on the registry; 13 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must understand and comply with the study procedures, voluntarily participate, and sign the form.
  2. Male subjects must weigh at least 50 kg; female subjects must weigh at least 45 kg.
  3. Vital signs, physical examination, laboratory tests, electrocardiography (), chest X-ray, and abdominal ultrasound (liver, gallbladder, spleen, pancreas, and both kidneys) are normal, or abnormalities are judged by the investigator to be clinically insignificant.
  4. Female subjects of or male subjects must agree to use effective from the time of signing the informed consent form until 6 months after the last dose of study drug.
  5. Subjects must have received stable treatment with nucleos(t)ide analogues (NAs) (e.g., entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide) for at least 6 months prior to screening.
  6. \< 90 IU/mL at screening.
  7. HBsAg > 100 IU/mL at screening.
  8. Serum and AST ≤ 2 × , and total serum ≤ 2 × ULN at screening and baseline.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have undergone major surgery within 3 months prior to screening, or plan to undergo surgery during the study period.
  2. Subjects with a history of allergy to the study drug or any of its components, or with allergic diathesis (allergic to two or more types of drugs or foods).
  3. Subjects with a history of alcohol abuse within 1 year prior to screening , or those with a positive blood alcohol test result prior to dosing.
  4. Subjects with a history of drug abuse or use of illicit drugs within 1 year prior to screening, or those with a positive urine drug screening result prior to dosing.
  5. Subjects who donated blood ≥200 mL, or donated any blood component, or suffered a total blood loss ≥200 mL for any reason within 3 months prior to screening; or those with a history of blood transfusion or blood product administration.
  6. Subjects who participated in another clinical trial within 3 months prior to screening.
  7. Subjects who develop an acute illness (e.g., acute respiratory disease) or receive concomitant medication from the time of signing the form to prior to the first dose.
  8. Subjects who are breastfeeding or have a positive serum pregnancy test result.
  9. Subjects with significant hepatic fibrosis or liver cirrhosis.
  10. Subjects with a history of hepatic decompensation manifestations or disease at screening or in the past, including but not limited to ruptured esophageal and gastric variceal bleeding, ascites, hepatic encephalopathy, etc.
  11. Subjects diagnosed with any malignant tumor within 5 years prior to screening , or those assessed to have potential malignant tumors at present.
  12. Subjects with (INR) >1.5, or count \<90×10⁹/L, or serum albumin \<35 g/L at screening.
  13. Subjects with alpha-fetoprotein (AFP) >50 ng/mL at screening.
  14. Subjects with endogenous (CLcr) \<60 mL/min/1.73 m² at screening.
  15. Subjects receiving, or who have received any interferon-containing regimen or therapy within 1 year prior to screening.
  16. Subjects whom the investigator considers unsuitable for participation in this trial for any other reasons.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    HECN30227 50~800 mg

    Drug: HECN30227 injection(SAD) · Drug: Placebo(SAD)

  • Experimental
    HECN30227 100~400 mg

    Drug: Placebo(MAD) · Drug: HECN30227 injection (MAD)

Interventions

  • DrugHECN30227 injection(SAD)

    single subcutaneous administrations

  • DrugPlacebo(MAD)

    0.9% Sodium Chloride Injection

  • DrugPlacebo(SAD)

    0.9% Sodium Chloride Injection

  • DrugHECN30227 injection (MAD)

    multiple subcutaneous administrations

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events In Part 1

    A summary of adverse events, including Serious Adverse Events(SAEs)

    Time frame: 85 days

  2. Number of Adverse Events In Part 2

    A summary of adverse events, including Serious Adverse Events(SAEs)

    Time frame: 169days

Secondary outcomes

  1. Peak Plasma Concentration (Cmax) of single dose

    Time frame: 48 h

  2. Peak Plasma Concentration (Cmax) of Multiple dose

    Time frame: 57 days

  3. Area under the plasma concentration-time curve(AUC0-t)

    Time frame: 57 days

  4. Time to the peak plasma concentration (Tmax)

    Time frame: 57 days

  5. Maximum Change of Serum HBsAg From Baseline

    Time frame: 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Apr 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2026
First posted
Aug 18, 2026
StartActual
Dec 2, 2025
Primary completionEst.
Apr 11, 2027
CompletionEst.
Apr 11, 2027
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07771140
Responsible party
Sponsor
First posted
Aug 18, 2026
Start date
Dec 2, 2025
Primary completion
Apr 11, 2027 (estimated)
Completion
Apr 11, 2027 (estimated)
Last update
Aug 18, 2026

Study contacts

wei Hu
Contact
hwgcp@ayefy.com
13856086475

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion